InflaRx N.V.
NASDAQ:IFRXBiotechnology
-$0.02 today
- Market cap
- $160.63M
- Beta
- 2.44
- P/E (TTM)
- -2.7
- EPS (TTM)
- -$0.59
Volume 0.66M
Average 1.80M
Returns on capital
InflaRx N.V. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-109.9%
avg -34.0%
ROIC
-113.6%
avg -54.9%
ROA
-82.7%
avg -48.4%
Analysis
ROA is currently the strongest return metric at -82.7% versus its period average of -48.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Maria Habel | Vice President, Head of Preclinical R&D and QC | — | 44 | — | — |
Thomas Taapken | Chief Financial Officer | — | 61 | 3.50K | <0.01% |
Christian Schmid | Vice President and Head of Legal Affairs & General Counsel | — | — | — | — |
Daniel Vetter | Senior Director & Head of IT | — | — | — | — |
Jan Medina | Head of Investor Relations & Vice President | — | — | — | — |
Kofi Boaten | VP and Head of Supply Quality & Clinical Trial Supplies | — | — | — | — |
Peter Hurt | Senior Director and Head of Drug Safety & Pharmacovigiliance | — | — | — | — |
Derval O'Carroll | Senior Vice President and Global Head of Regulatory Affairs & Compliance | — | 60 | 20.00K | 0.03% |
Niels C. Riedemann | Co-Founder, Chief Executive Officer & Executive Director | — | 53 | — | — |
Renfeng Guo | Co-Founder, Chief Scientific Officer & Executive Director | — | 56 | 5.41K | <0.01% |
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Mar 18, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
No open-market purchases or sales in the last 12 months.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | +216.8% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Forward estimates point to Revenue at +216.8% (5yr), giving you a quick read on expected growth from here.
Competitors
Who does InflaRx N.V. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about IFRX's management, answered from reported figures.
Who manages IFRX?
InflaRx N.V. (IFRX) lists 10 active executives. The top listed executive is Maria Habel, Vice President, Head of Preclinical R&D and QC.
Are IFRX insiders buying or selling?
Recent insider activity shows net buying of $0.00.
Continue the stock analysis
Jump to another research area for this company.